Joint Formulary & PAD

Fremanezumab - Migraine (prevention)

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Subcutaneous injection (sc)
Associated Icons :
Restrictions / Comments :

PAD Profile

ChemicalSubstance :
Fremanezumab
Indication :
Migraine (prevention)
Group Name :
Keywords :
calcitonin gene-related peptide inhibitors, anti-CGRP, migraine prevention, chronic migraine, episodic migraine
Brand Names Include :
Ajovy
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Supporting Documents :
2

Other Indications

Below are listed other indications that Fremanezumab is used to treat.

  • No records returned.

Committee Recommendations (1)

The Surrey Heartlands Integrated Care System Area Prescribing Committee recommends fremanezumab as a treatment option for preventing migraine in line with NICE TA764

Fremanezumab will be considered RED on the traffic light system. Prescribing will be by hospital specialists only, in line with NICE TA764.

Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.